Newsroom
Lawsuits Filed Against Revance Therapeutics Inc. Over Securities Violations
By KlickAnalytics Data Insights | January 10, 2025 08:02PM ET
Key Points
- Multiple law firms have initiated class action lawsuits against Revance Therapeutics Inc.
- Investors who suffered losses due to alleged securities violations have the opportunity to lead the class action lawsuit.
- The lawsuits seek to recover damages on behalf of investors who purchased Revance securities within a specific timeframe.
- Investors are encouraged to contact the respective law firms before a specified deadline to discuss their rights.
- The lawsuits claim violations of federal securities laws by Revance Therapeutics Inc.
Bronstein, Gewirtz & Grossman LLC, Levi & Korsinsky LLP, The Schall Law Firm, and Kirby McInerney LLP have all taken legal action against Revance Therapeutics Inc., alleging violations of federal securities laws. These law firms have filed class action lawsuits on behalf of investors who incurred losses due to these alleged violations.
The lawsuits target Revance Therapeutics Inc. and some of its officers, seeking to recover damages for investors who purchased or acquired Revance securities during specific periods. The class definition aims to cover all individuals and entities who bought or otherwise obtained Revance securities between the dates outlined in the lawsuits.
Investors who suffered losses as a result of their investments in Revance Therapeutics Inc. are urged to contact the law firms involved in the class action lawsuits before the specified deadlines. These firms are offering the opportunity for affected investors to discuss their rights and potential paths to recovery under the federal securities laws.
The legal actions follow claims of securities fraud and violations of the Securities Exchange Act of 1934, particularly rules 10(b) and 20(a) promulgated by the U.S. Securities and Exchange Commission. The lawsuits allege that Revance Therapeutics Inc. engaged in activities that adversely affected investors during the defined class period.
Investors should take prompt action in response to these lawsuits to determine the best course of action regarding their investments in Revance Therapeutics Inc. It is essential for affected individuals and entities to engage with the legal process to understand their rights and explore potential avenues for recovering losses incurred as a result of the alleged securities violations.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with